ImmunityBio
Tracked across 1 events · 188 articles · First seen Jan 29, 2026 · Last active Apr 18, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Regulatory
ImmunityBio faces multiple class action lawsuits and an FDA warning letter regarding misleading claims about its drug Anktiva, leading to a significant drop in its stock price and erasing nearly $2 billion of its market capitalization.
Jan 29, 2026 · 188 articles
95
United States===Food and Drug Administration issued a warning letter regarding misleading promotions ImmunityBioImmunityBio Faces Lawsuits...
95
United States===Food and Drug Administration issued warning letter regarding misleading drug promotions ImmunityBioImmunityBio Faces Lawsuits...
90
ImmunityBio stock price fell by 12.13%ImmunityBio Faces Lawsuits...
90
ImmunityBio promoted Anktiva with misleading efficacy claimsImmunityBio Faces Lawsuits...
90
Pomerantz LLP initiated investigation into potential securities fraud ImmunityBioImmunityBio Faces Lawsuits...
90
Pomerantz LLP filed a class action lawsuit ImmunityBioImmunityBio Faces Lawsuits...
85
ImmunityBio promoted Anktiva in a misleading mannerImmunityBio Faces Lawsuits...
85
ImmunityBio stock price fell by over 21%ImmunityBio Faces Lawsuits...
+ 9 more actions
View on Dashboard
Patrick Soon-Shiong
executive chairman and Chief Scientific and Medical Officer
↔
ImmunityBio
Patrick Soon-Shiong is the executive chairman and Chief Scientific and Medical O
Richard Adcock
CEO
↔
ImmunityBio
Richard Adcock is the CEO of ImmunityBio, a publicly traded company.
NEWSDESK
Track ImmunityBio live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard